Related Experiment Video
Updated: Jul 27, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Inhibiting the expression of CD28 costimulatory molecule on human lymphocytes by special siRNA
Kai-lin Xu1, Ying Zhang, Xiu-ying Pan
1Department of Hematology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China. xukailin@hotmail.com
Background:
The B7/CD28 pathway provides critical costimulatory signals for complete T cell activation, and members of this pathway have served as useful targets for immunotherapeutic strategies. In this study, we investigated the RNA interference (RNAi) effect induced by small interfering RNA (siRNA) targeting CD28 mRNA on human lymphocytes and its specificity.
Methods:
According to CD28 gene sequence, we designed and synthysized three different siRNAs (siRNA-1, siRNA-2, siRNA-3) containing 21 bases using Silencertrade mark siRNA construction kit. These siRNAs were transfected into freshly isolated human lymphocytes with Lipofectamine 2000 reagent. At 24-hour, 48-hour and 72-hour post transfection, these cells were collected and analyzed. The changes of surface expression of CD28 gene were detected by flow cytometry, and the changes of CD28 mRNA levels were determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). The cell viability of transfected lymphocytes was determined by methyl thiazolyl tetrazolium (MTT) assay and trypan blue dye exclusion assay.
Results:
Three siRNAs (siRNA-1, siRNA-2, siRNA-3) specifically targeting CD28 mRNA were successfully designed and constructed. Flow cytometry analysis showed that a decrease in CD28 expression was detectable at 24-hour post transfection. Different siRNA showed different inhibition effects on CD28 expression. At 48-hour post transfection, the degrees of reduction with siRNA-1, siRNA-2 and siRNA-3 were 22.10% +/- 1.63%, 73.50% +/- 1.02% and 42.90% +/- 0.89% respectively compared with the control (P < 0.001). Neither of the groups transfected only with siRNA or lipo showed marked reduction in CD28 expression (3.15% +/- 0.75% and 4.55% +/- 0.80%) (P > 0.05). Moreover, lymphocytes treated with siRNA-co showed no marked reduction in CD28 expression (5.07% +/- 0.96%) (P > 0.05). The results of semi-quantitative RT-PCR assay indicated CD28 mRNA level was inhibited after transfection of specific siRNAs. At least 4-fold of reduction in siRNA-2 group occurred at 48-hour post transfection compared with the control (P < 0.001). MTT assay and trypan blue dye exclusion assay demonstrated that the viable cell rations of transfected lymphocytes were significantly reduced in siRNA-1, siRNA-2 and siRNA-3 groups at 48-hour post transfection (P < 0.01). The control groups showed no marked reduction in cell viability (P > 0.05).
Conclusions:
Three different siRNAs were synthesized and transfected into lymphocytes. They could reduce the expression of CD28 and the CD28 mRNA level. siRNA-2 was the most efficient. The cell viability reduced correspondingly. Therefore, the silencing effect on CD28 mRNA induced by siRNA may contribute to costimulatory blockade. This result show that siRNA may be useful for further study on graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (allo-BMT).
Insights
Small interfering RNA (siRNA) targeting CD28 mRNA effectively reduces CD28 expression and mRNA levels in human lymphocytes. siRNA-2 demonstrated the highest efficiency, leading to reduced cell viability and potential applications in costimulatory blockade for graft-versus-host disease.
Area of Science:
- Immunology
- Molecular Biology
- RNA Interference
Background:
- The B7/CD28 pathway is crucial for T cell activation and a target for immunotherapy.
- Investigating RNA interference (RNAi) induced by small interfering RNA (siRNA) targeting CD28 mRNA in human lymphocytes.
Purpose of the Study:
- To evaluate the RNA interference (RNAi) effect and specificity of siRNAs targeting CD28 mRNA in human lymphocytes.
- To assess the impact of CD28 mRNA silencing on T cell activation and viability.
Main Methods:
- Design and synthesis of three distinct 21-base siRNAs targeting CD28 mRNA.
- Transfection of siRNAs into human lymphocytes using Lipofectamine 2000.
- Analysis of CD28 surface expression (flow cytometry) and mRNA levels (RT-PCR) at 24, 48, and 72 hours post-transfection.
- Assessment of cell viability using MTT assay and trypan blue dye exclusion assay.
Main Results:
- Successfully designed and constructed three siRNAs targeting CD28 mRNA.
- Significant reduction in CD28 expression observed starting at 24 hours post-transfection, with siRNA-2 showing the highest inhibition (73.50% +/- 1.02%) at 48 hours.
- RT-PCR confirmed CD28 mRNA level inhibition, with siRNA-2 causing at least a 4-fold reduction.
- Transfection with siRNAs led to a significant reduction in viable lymphocyte counts.
Conclusions:
- Synthesized siRNAs effectively reduced CD28 expression and mRNA levels in lymphocytes, with siRNA-2 being the most potent.
- The observed reduction in CD28 expression and cell viability suggests siRNA-induced silencing may contribute to costimulatory blockade.
- These findings indicate siRNA's potential utility in further research on graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (allo-BMT).
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity

